RPL13 and breast cancer: Our analysis confirmed the down-regulation of RPL13, and newly identified down-regulation of HDAC1, ANP32A, and the up-regulation of SNX2 as having the worst prognostic effects in normal-subtype breast cancer tumors (Fig. 8C, panels C4–C7).